Don't practice another day without reading between the lines of this release; it is all true.

We all need more vitamin K-2 and lots of it to stop the calcification of our vessels and increase the strength of our bones. Everyone at age 80 has 140 times too much calcium in their aorta. Fight back now and learn this!!

Please read this release very carefully. Longevity Plus is the only source I know of, at this time, where you can treat your patients with affordable 10 mg of the correct form of K2 twice a day and achieve a therapeutic result. We have seen an 8 % increase in bone density in 8 months but now you will become as excited as I have been. This is the key to controlling calcification of our blood vessels; this is the beginning of the end for the Bypass and Stenting guys. I have spent 30 years studying pathologic calcification. My diatribes are readily reviewed on both websites, FACT and my public site http://www.gordonresearch.com, and there is different information on both, as I do not duplicate on FACT things I have completely covered in the past on my main site.

This is on top of what I teach about secondary hyperparathyroidism due to high phosphorus in the diet. We all must take the 500 mg of calcium supplement found in Beyond Any Multiple (BAM), the multiple found in Beyond Chelation Improved. But that is the tip of the iceberg. Magnesium is key and, of course, ideally as least as much as the calcium, or even more if you can avoid the diarrhea. But Boron and Vit D and now that we have HRT to deal with hormonal aspects of pathologic calcification you must stop all bone loss of calcium and Beyond Bone Defense does that when taken in conjunction with the HRT. However, always get the lead out so that the calcium pump can operate efficiently, and so on. Use Search and use the word calcification.

But now, if you read this document, you will never again ever see a patient with calcification of vessels without immediately getting them on K2, as found with all of the other tricks that I could find to stop bone loss and permit stronger bones and softer, less calcified, blood vessels. This story will surface in the coming months and you can count on this being true and important!

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
http://www.gordonresearch.com

For Immediate Release
20 September 2006

New Patent-pending Indications for Natural Vitamin K2 Announced by PL Thomas in Strategic Alliance with Natto Pharma and VitaK BV

PL Thomas & Company (PLT) of Morristown, NJ today announced new patent-pending indications for its Natural Vitamin K2 marketed under the trademark MenaQ7(TM). The role of Natural Vitamin K2 in bone health is well established, and recent research has shown that of the group of K vitamins, only K2 is linked to cardiovascular health. The alliance between PLT, Natto Pharma, Norway and VitaK BV now allows MenaQ7 to be offered for cardiovascular benefits with proprietary research and US patents pending.

PLT is the exclusive North American representative for Natto Pharma, Norway, the supplier of MenaQ7. Natto Pharma, as part of the Strategic Alliance, has acquired three US patents pending from VitaK, which is closely associated with the Cardiovascular Research Institute, University of Maastricht, The Netherlands. Further, Natto Pharma has committed to a five-year, multimillion dollar research initiative with VitaK, whereby the proprietary research and subsequent intellectual property developed will be owned by Natto Pharma.

According to Professor Cees Vermeer, PhD, CEO of VitaK, "We have reached full agreement with NattoPharma regarding the purchase of our three patents in the K2-nutrition area. The most important claims are the use of K2 in nutraceuticals, the use of K2 regarding cardiovascular disease/mortality and regression of arterial calcification, and the combinations of K2 and important nutrients including Omega-3 fatty acids."

"These patents support Natto Pharma's natural vitamin K2," Professor Vermeer continued, "the natural vitamin K2 stability, absorption, activity and efficacy have only been tested (at least in our lab) with the material marketed by NattoPharma and PL Thomas."

PL Thomas President Paul Flowerman commented, "we are delighted to present to our clients what we firmly believe is the most viable Vitamin K2 opportunity in all respects. MenaQ7 directly addresses important bone and cardiovascular wellness issues. It is manufactured under cGMP conditions, reliably supplied, and is supported by a total commitment to the best existing and ongoing research and intellectual property development. "

About MenaQ7
MenaQ7 provides Natural Vitamin K2 as an extract of natto, a fermented soy food from Japan. Natto is particularly rich in the highly bio-available form of vitamin K2 called menaquinone-7 (MK-7). Studies of Natto consumption in Japan have linked menaquinone-7 to greater bone health and reduction in risk factors.

Natural Vitamin K2 also may provide significant benefit to cardiovascular health due to its roles in calcium utilization and promoting matrix Gla-protein, a potent inhibitor of vascular calcification. For example, in a study published in The Journal of Nutrition with over 4,700 participants, those with the highest natural K2 consumption had a 50% reduction in risk of cardiovascular events.

About PL Thomas
PL Thomas, a New Jersey-based ingredient supplier, offers fifty years of innovation in securing reliable, high quality raw materials for the food/functional food and nutrition industries. PLT is a one-stop resource for application solutions, current industry information and technical service, and specializes in water-soluble gums and clinically-supported botanical extracts.

For more information, please visit our website (http://www.plthomas.com/MenaQ7.htm) or contact Eric Anderson at 973-984-0900, x215 or eric@plthomas.com.